UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Ra'anana, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-768-9780
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.13 million
Profitability
Miscellaneous
Employees70
Next Earnings Date5/21/2019 (Estimated)
OptionableOptionable
Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions
What is Urogen Pharma's stock symbol?
Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."
How were Urogen Pharma's earnings last quarter?
Urogen Pharma Ltd (NASDAQ:URGN) issued its quarterly earnings data on Thursday, February, 28th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.29) by $0.17. Urogen Pharma had a negative net margin of 4,296.08% and a negative return on equity of 70.67%. View Urogen Pharma's Earnings History.
When is Urogen Pharma's next earnings date?
What price target have analysts set for URGN?
6 analysts have issued 12-month target prices for Urogen Pharma's shares. Their predictions range from $57.00 to $77.00. On average, they expect Urogen Pharma's stock price to reach $68.40 in the next twelve months. This suggests a possible upside of 87.1% from the stock's current price. View Analyst Price Targets for Urogen Pharma.
What is the consensus analysts' recommendation for Urogen Pharma?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.
What are Wall Street analysts saying about Urogen Pharma stock?
Here are some recent quotes from research analysts about Urogen Pharma stock:
- 1. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating on URGN shares post its 4Q18 financial report and business update. We remain bullish on its lead program, MitoGel (UGN-101) which is being developed as a non-surgical treatment option for patients with upper tract urothelial carcinoma (UTUC), a niche, but high unmet need patient population. We continue to await the completion of URGN’s OLYMPUS Phase 3 study for MitoGel in UTUC, which we previously estimated could finish in the August 2019 timeframe in order for ~75% of patients achieving a CR to reach the 6-month time point. While there was not much new in terms of an update on last week’s conference call, we believe the company remains well positioned to execute on its plan to complete its rolling NDA submission in the 2H19 setting up a 1H20 launch along with the ability to leverage its RTGel platform for business development opportunities." (3/5/2019)
- 2. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (11/17/2018)
Has Urogen Pharma been receiving favorable news coverage?
News coverage about URGN stock has trended positive on Saturday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Urogen Pharma earned a daily sentiment score of 2.6 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the company's share price in the near term.
Who are some of Urogen Pharma's key competitors?
Some companies that are related to Urogen Pharma include AnaptysBio (ANAB), Endocyte (ECYT), Myokardia (MYOK), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Xencor (XNCR), Ironwood Pharmaceuticals (IRWD), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Enanta Pharmaceuticals (ENTA), Madrigal Pharmaceuticals (MDGL), Allakos (ALLK), Endo International (ENDP) and Zogenix (ZGNX).
What other stocks do shareholders of Urogen Pharma own?
Who are Urogen Pharma's key executives?
Urogen Pharma's management team includes the folowing people:
- Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 57)
- Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 50)
- Mr. Stephen Mullennix, Chief Operating Officer
- Ms. Catherine Bechtold, Director of Corp. Communications & Investor Relations
- Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director
When did Urogen Pharma IPO?
(URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
Who are Urogen Pharma's major shareholders?
Urogen Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Tibra Equities Europe Ltd (0.25%) and Harel Insurance Investments & Financial Services Ltd. (0.01%). Company insiders that own Urogen Pharma stock include Mark Schoenberg and Proquest Investments Iv, LP. View Institutional Ownership Trends for Urogen Pharma.
Which major investors are buying Urogen Pharma stock?
How do I buy shares of Urogen Pharma?
Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Urogen Pharma's stock price today?
One share of URGN stock can currently be purchased for approximately $36.56.
How big of a company is Urogen Pharma?
Urogen Pharma has a market capitalization of $502.74 million and generates $1.13 million in revenue each year. The company earns $-75,660,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Urogen Pharma employs 70 workers across the globe.
What is Urogen Pharma's official website?
How can I contact Urogen Pharma?
Urogen Pharma's mailing address is 499 Park Avenue, New York NY, 10014. The company can be reached via phone at 646-768-9780 or via email at [email protected]
MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
